profit from every $100 of sales.
$0$100
Summit Therapeutics
$14.15-6.14% today
-22.5% in 1 year
1-year low $12.431-year high $26.38
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2019 to 2022.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Summit Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $705,000 in 2022 to $0 in 2025, with -$1.08 billion of profit last year.
SalesProfit
Summit Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Summit Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Summit Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1 | 2 | 1 | 0 | 0 | 0 | |
| – | – | – | – | – | – | |
| – | – | -64 | -89 | -211 | -1,094 | |
| -51 | -87 | -73 | -598 | -213 | -1,079 | |
| -53 | -89 | -79 | -615 | -221 | -1,080 | |
| -0.76 | -0.67 | -0.41 | -0.99 | -0.31 | -1.44 | |
| – | – | – | – | – | – | |
| – | – | -9,024.3% | – | – | – | |
| -6,127.6% | -4,897.8% | -11,174.8% | – | – | – |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 102 | 113 | 664 | 203 | 436 | 751 |
| Cash | 66 | 72 | 349 | 71 | 105 | 225 |
| Total debt | – | – | 519 | 106 | 7 | 21 |
| Total liabilities | 23 | 30 | 538 | 125 | 47 | 92 |
| 79 | 83 | 127 | 78 | 389 | 659 | |
| 70 | 132 | 193 | 620 | 719 | 748 | |
| -52.4% | -83.8% | -9.1% | -257.2% | -42.4% | -125.5% | |
| -66.3% | -106.4% | -62.2% | -791.5% | -56.9% | -163.9% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -48 | -73 | -42 | -77 | -142 | -323 | |
| 0 | 0 | 1 | 0 | 0 | 1 | |
| -49 | -73 | -42 | -77 | -142 | -324 | |
| Dividends paid | 0 | – | – | – | – | – |
| – | – | – | – | – | – | |
| 2 | 13 | 12 | 14 | 51 | 732 |
Valuation
- –
- –
- –
- 31.6×
- 16,052.0×
- –
- –
- -0.4%
- -0.7%
- 0.0%
Profitability
- 0.0%
- -9,024.3%
- -11,174.8%
- 0.0%
- -248.1%
- -143.3%
- -340.6%
- -214.2%
- -249.5%
- –
Growth
- −76.9%
- –
- −111.3%
- –
- +68.7%
Financial health
- –
- 0.04
- 3.1%
- –
- 7.41
- 7.41
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 908
Bottom 34%of 991
What analysts expect
- Average price target
- $19.00
- Range
- $16.00 – $23.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.24 | -0.33 | +27.3% |
| Feb 23, 2026 | -0.29 | -0.10 | −182.5% |
| Oct 20, 2025 | -0.31 | -0.18 | −76.4% |
| Aug 11, 2025 | -0.76 | -0.09 | −736.9% |
| May 1, 2025 | -0.09 | -0.09 | +3.2% |
| Feb 24, 2025 | -0.08 | -0.08 | +2.2% |
| Oct 30, 2024 | -0.08 | -0.07 | −14.3% |
| Aug 6, 2024 | -0.05 | -0.06 | +16.7% |
News
Huang's exit, AI bubble and financial crisis fears in focus on Web Summit's last dayYahoo Finance · Nov 13, 2026Jensen Huang pulls out of ElevenLabs Summit amid Nvidia controversyYahoo Finance · Nov 9, 2026Federal Realty signals $7.54-$7.58 core FFO per share guidance while integrating $508M The Summit acquisitionSeeking Alpha · Oct 30, 2026Miami AI Summit Draws 700+ for Sold-Out Gathering of Global AI and Emerging Tech LeadersYahoo Finance · Oct 26, 2026Summit Therapeutics reports survival benefit for cancer drug in trialSeeking Alpha · Oct 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
11No pass
Benjamin Graham
40No pass
Philip Fisher
23No pass
Peter Lynch
100Pass
Joel Greenblatt
0No pass
Charlie Munger
20No pass
Terry Smith
16No pass
Questions about Summit Therapeutics
Is Summit Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Summit Therapeutics AI analysis
What does Summit Therapeutics do?
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). It is in Biotechnology, based in Miami, FL, United States, with 265 employees.
Does Summit Therapeutics pay a dividend?
No. Summit Therapeutics does not pay a dividend at the moment.
Is Summit Therapeutics stock halal?
Yes. Summit Therapeutics passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Summit Therapeutics stock done over the past year?
Down 22.5% over the past twelve months, to $14.15. It traded between $12.43 and $26.38 and is 46.4% below its high.
Who are Summit Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Summit Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.